Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03648632

Stereotactic Radiotherapy (SBRT) in Patients With Locally Advanced Pancreatic Cancer (LAPC) — SBRT-PC-01  

Locally Advanced Pancreatic Cancer Clinical Trial

Official title:
Stereotactic Radiotherapy (SBRT) in Patients With Locally Advanced Pancreatic Cancer (LAPC). A Danish Phase II Study

Clinical Trial Summary

Stereotactic Radiotherapy (SBRT) in patients with locally advanced pancreatic cancer (LAPC). A Danish phase II study.

Clinical Trial Description

Combination chemotherapy (e.g. FOLFIRINOX (5-fluorouracil, irinotecan, oxaliplatin), Gem-Abraxane, Gem-Cap, Gem-S1) is standard of care in patients with LAPC but more and more scientific studies point to the fact that patients without sign of progressive disease (PD) will benefit from additional radiotherapy and especially SBRT. The sample size is based on Simon's two stages mini-max design. This design ensures early study termination if there is insufficient effect. A resection rate less than 10% after SBRT is not clinically acceptable. Assuming a significance level at 0.1 (α = 0.1) and a power at 90% (β = 0.10) it can be calculated, that 16 patients should be included in the first part of the study. The enrolment will continue until 16 patients have completed SBRT and have been re-evaluated for resection by CT scan (and endoscopic ultrasonography + laparoscopic ultrasound, if available). If 1 or less out of the first 16 consecutive patients are being resected the investigators will reject our hypotheses and close the study after the first stage of accrual. If 2 or more patients are resected, an additional 9 patients will be accrued in the second stage. If at least 4 out of 25 patients are resected, a true resection rate of 30% cannot be excluded, and the investigators will conclude that the treatment is effective enough to continue with future studies. To ensure 25 evaluable patients the investigators will include a total of 30 patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03648632
Study type Interventional
Source Odense University Hospital
Contact
Status Completed
Phase N/A
Start date August 22, 2018
Completion date March 31, 2022
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03600623 - Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Early Phase 1
Completed NCT01628458 - Safety Study of Radiofrequency Ablation of Locally Advanced Pancreatic Cancer Phase 2
Not yet recruiting NCT04276857 - Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer N/A
Not yet recruiting NCT05988372 - Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE) Phase 2
Completed NCT00744640 - Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma Phase 1/Phase 2
Completed NCT03126435 - EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX Phase 3
Completed NCT02035072 - Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer. Phase 2
Enrolling by invitation NCT01063192 - A Study of Locally Advanced Pancreatic Cancer Phase 2
Active, not recruiting NCT06429904 - Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer Phase 2
Recruiting NCT03885219 - Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer Phase 2
Active, not recruiting NCT03468335 - 2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy Phase 3
Not yet recruiting NCT03443921 - Divestment for Artery-involved Pancreatic Cancer N/A
Recruiting NCT03257033 - Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC Phase 3
Completed NCT02578732 - FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial Phase 2
Recruiting NCT04789980 - Good Choice of pALliative Chemotherapy to Patient With Pancreatic Cancer ; GemcitAbine Therapy vs FOLFORINOX therapY
Completed NCT00644618 - Randomized Controlled Trial of Gemcitabine Combined With 125I Brachytherapy Phase 3
Recruiting NCT03682289 - Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors Phase 2
Terminated NCT02404363 - Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy Phase 3
Active, not recruiting NCT06353581 - Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX Phase 2
Not yet recruiting NCT03815461 - Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer Phase 2